arginine butyrate (HQK-1004) / Viracta Therap, Boston University  >>  Phase 2
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
arginine butyrate (HQK-1004) / Boston University, Viracta Therap
NCT00992732: Study of HQK-1004 and Valganciclovir to Treat Epstein-Barr Virus (EBV) - Positive Lymphoid Malignancies or Lymphoproliferative Disorders

Terminated
2a
1
US
HQK-1004, arginine butyrate, Valganciclovir (may substitute with ganciclovir)
HemaQuest Pharmaceuticals Inc.
Lymphoid Malignancies, Lymphoproliferative Disorders
11/10
 
NCT00006136: Phase II Study of Arginine Butyrate With or Without Epoetin Alfa in Patients With Thalassemia Intermedia

Completed
2
15
US, Europe
arginine butyrate, epoetin alfa
Boston University
Beta-Thalassemia
 
 
NCT00917826: Study of Arginine Butyrate and Ganciclovir/Valganciclovir in EBV(+) Lymphoid Malignancies

Terminated
2
1
US
Arginine Butyrate, HQK-1004, Ganciclovir, Valganciclovir
HemaQuest Pharmaceuticals Inc., Boston University
EBV Lymphomas, Lympho-proliferative Diseases
09/09
 

Download Options